Go Pro

HC Wainwright Estimates Cibus' Q3 Earnings (NASDAQ:CBUS)

Cibus logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its Q3 2026 EPS estimate for Cibus to a loss of $0.27 per share from $0.24, while forecasting losses of $1.13 per share for fiscal 2026 and $1.07 for fiscal 2027.
  • Cibus reported a Q2 loss of $0.29 per share, missing the $0.19 consensus estimate, while revenue of $0.99 million fell short of the $1.70 million forecast.
  • The stock fell 5.6% and opened at $1.67; analysts’ consensus rating remains Hold, with an average price target of $9.00.
  • MarketBeat previews top five stocks to own in September.

Cibus, Inc. (NASDAQ:CBUS - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2026 EPS estimates for Cibus in a note issued to investors on Friday, August 14th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of ($0.27) for the quarter, down from their previous estimate of ($0.24). The consensus estimate for Cibus' current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Cibus' Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.50) EPS.

Cibus (NASDAQ:CBUS - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.10). The business had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.70 million. Cibus had a negative return on equity of 287.03% and a negative net margin of 2,258.89%.

Several other equities analysts also recently commented on the stock. Wall Street Zen raised shares of Cibus from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. Weiss Ratings cut Cibus from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, June 29th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Cibus presently has a consensus rating of "Hold" and an average price target of $9.00.

Check Out Our Latest Research Report on Cibus

Cibus Trading Down 5.6%

Cibus stock opened at $1.67 on Tuesday. Cibus has a 1-year low of $1.09 and a 1-year high of $4.19. The firm's fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.97. The company has a market capitalization of $127.47 million, a P/E ratio of -1.01 and a beta of 1.61.

Institutional Trading of Cibus

A number of institutional investors and hedge funds have recently modified their holdings of the company. Weiss Asset Management LP bought a new stake in shares of Cibus during the 1st quarter worth $1,758,000. Prescott Group Capital Management L.L.C. bought a new position in Cibus in the 4th quarter worth $345,000. Jane Street Group LLC bought a new position in Cibus in the 2nd quarter worth $207,000. Certior Financial Group LLC lifted its position in Cibus by 46.7% during the 4th quarter. Certior Financial Group LLC now owns 271,164 shares of the company's stock worth $472,000 after acquiring an additional 86,378 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new position in Cibus during the 4th quarter worth $145,000. 33.81% of the stock is currently owned by institutional investors and hedge funds.

About Cibus

(Get Free Report)

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company's platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company's core business centers on trait development services and licensing partnerships.

Further Reading

Earnings History and Estimates for Cibus (NASDAQ:CBUS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Cibus Right Now?

Before you consider Cibus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cibus wasn't on the list.

While Cibus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines